LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24BSX&src=ctag” target=”_blank”gt;$BSXlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP (“GPM”), a national investors rights law
firm, announces that a class action lawsuit has been filed on behalf of
investors that acquired Boston Scientific Corporation (“Boston
Scientific” or the “Company”) (NYSE: BSX)
securities between February 26, 2015 and April 16, 2019, inclusive
(the “Class Period”). Boston Scientific investors have until June
24, 2019 to file a lead plaintiff motion.
If you are a shareholder who suffered a loss, click here
to participate.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.
On April 16, 2019, the Company was ordered by the U.S. Food and Drug
Administration (“FDA”) to stop selling and distributing its surgical
mesh products. According to the FDA, the Company had “not demonstrated a
reasonable assurance of safety and effectiveness for these devices.”
On this news, the Company’s share price fell $2.90 per share, more than
7%, over the following two trading sessions to close at $34.91 per share
on April 17, 2019, thereby injuring investors.
The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Boston Scientific’s
surgical mesh products indicated for the transvaginal repair of POP were
unsafe; (2) accordingly, Boston Scientific’s continued marketing and
sales of these devices in the United States was unlikely to be
sustainable; (3) separately, the Company had sold vaginal mesh implants
containing counterfeit or adulterated resin products imported from
China; (4) the foregoing conduct subjected the Company to a heightened
risk of regulatory scrutiny and/or government investigations; and (5) as
a result, the Company’s public statements were materially false and
misleading at all relevant times.
Follow us for updates on Twitter: twitter.com/GPM_LLP.
If you purchased shares of Boston Scientific during the Class Period you
may move the Court no later than June 24, 2019 to ask
the Court to appoint you as lead plaintiff. To be a member of the Class
you need not take any action at this time; you may retain counsel of
your choice or take no action and remain an absent member of the Class.
If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, of
GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at
310-201-9150, Toll-Free at 888-773-9224, by email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.
This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
www.glancylaw.com
[email protected]
